Dendreon Corp fka DNDNQ

[ocyanblue]

<CEGE clains that the Ph3 GVAX dosing is at the highest dose level given in its Ph2 trials and that median survival at that dose was 35 months. This GVAX dosing without Taxotere equates to the median survival that Dr. Petrylak reported for the 51 ITT patients in 9901 and 9902a that took Taxotere after Provenge and will be compared to a Taxotere control arm where Taxotere had a median survival of 23 months in the assymptomatic subgroup in its clinical trials.>

When you look at medians, beware of small numbers. The GVAX median survival of 35 months was for 10 patients with a range (8,57). This is way too sparse to be reliable. It would have been nicer if they reported the survival times of a few patients around the median to give some idea of how far apart they were. As this data is way too optimistic and given the nature of an open trial with a tiny number of patients, it would not surprise me if Vital-1 will yield wildly different results much more negative than shown here.